Financial Position - The company has approximately $27.3 million in cash and cash equivalents and marketable securities as of September 30, 2025[120]. - As of September 30, 2025, the company does not believe its existing cash and cash equivalents will fund operations for at least twelve months, raising substantial doubt about its ability to continue as a going concern[154]. - The company completed a private placement in April 2024, raising approximately $50.0 million, with potential additional proceeds of up to $99.4 million from warrant exercises[150]. Revenue and Grant Funding - The accumulated deficit as of September 30, 2025, is $89.6 million, with a net loss of $18.9 million for the nine months ended September 30, 2025[121]. - Grant funding recognized for the nine months ended September 30, 2025, was $4.0 million, compared to $7.6 million for the same period in 2024[123]. - Grant revenue decreased to $0.3 million for the three months ended September 30, 2025, down from $1.9 million in 2024, representing an 83% decline[132]. - For the nine months ended September 30, 2025, grant revenue was $4.0 million, down 47% from $7.6 million in 2024[141]. Operating Expenses - Total operating expenses for the three months ended September 30, 2025, increased to $8.4 million, a 14% rise from $7.3 million in 2024[131]. - Total operating expenses for the nine months ended September 30, 2025, were $24.0 million, a 29% increase from $18.6 million in 2024[140]. - Research and development expenses rose to $6.0 million for the three months ended September 30, 2025, an 18% increase from $5.1 million in 2024[135]. - Research and development expenses for the nine months ended September 30, 2025, totaled $16.0 million, a 37% increase from $11.7 million in 2024[145]. Net Loss - Net loss for the three months ended September 30, 2025, was $7.7 million, a 63% increase compared to a net loss of $4.8 million in 2024[131]. - The net loss for the nine months ended September 30, 2025, was $18.9 million, up from a net loss of $9.6 million in the same period of 2024, indicating a 97% increase in losses[158][159]. Cash Flow - For the nine months ended September 30, 2025, net cash used in operating activities was $16.9 million, compared to $8.5 million for the same period in 2024, representing a 99% increase in cash outflow[157][158]. - Cash provided by financing activities for the nine months ended September 30, 2025, was $4.6 million, a significant decrease from $46.4 million in the same period of 2024, reflecting a decline of 90%[161]. - Cash used in investing activities for the nine months ended September 30, 2025, was $12.7 million, down from $38.0 million in the same period of 2024, showing a reduction of 66%[160]. Clinical Trials and Research - The RewinD-LB Trial demonstrated a 54% risk reduction in clinically significant worsening compared to control at Week 32 of Batch B neflamapimod treatment (p=0.0037)[116]. - Neflamapimod has shown statistically significant improvements in primary and secondary endpoints in the RewinD-LB Trial (p < 0.001 for primary endpoint)[114]. - The company plans to initiate a Phase 3 clinical trial for neflamapimod in approximately 300 patients with DLB in the second half of 2026[117]. - The company expects topline data from the ongoing RESTORE Trial, evaluating neflamapimod in ischemic stroke recovery, in the second half of 2026[118]. - Manufacturing improvements are being implemented to ensure the stability of the drug product for the planned Phase 3 trial[119]. Future Outlook - Research and development expenses are expected to increase substantially as the company continues to invest in clinical trials and regulatory approvals[126]. - The company anticipates continued increases in research and development expenses, general and administrative expenses, and capital expenditures in the foreseeable future[153]. - The company plans to finance its cash needs through equity offerings, debt financings, or other capital sources, which may dilute existing stockholders' ownership[154]. - The company is focused on advancing its product candidates through clinical development and may require additional funds to meet operational needs[155]. Accounting Policies - There were no material changes to the company's critical accounting policies and estimates during the nine months ended September 30, 2025[165]. - The company has no off-balance sheet arrangements that could materially affect its financial condition[164].

Financial Position - The company has approximately $27.3 million in cash and cash equivalents and marketable securities as of September 30, 2025[120]. - The accumulated deficit as of September 30, 2025, is $89.6 million, with a net loss of $18.9 million for the nine months ended September 30, 2025[121]. - As of September 30, 2025, the company had approximately $27.3 million in cash and cash equivalents, with an accumulated deficit of approximately $89.6 million[149]. - The company completed a private placement in April 2024, raising approximately $50.0 million, with potential additional proceeds of up to $99.4 million from warrant exercises[150]. - Cash provided by financing activities for the nine months ended September 30, 2025, was $4.6 million, a significant decrease from $46.4 million in the same period of 2024, reflecting a decline of approximately 90%[161]. - Cash used in investing activities for the nine months ended September 30, 2025, was $12.7 million, compared to $38.0 million in the same period of 2024, showing a reduction of about 66%[160]. - As of September 30, 2025, the company does not believe its existing cash and cash equivalents will fund operations for at least twelve months, raising substantial doubt about its ability to continue as a going concern[154]. Revenue and Grant Funding - The company has not generated any revenue from product sales and does not expect to do so in the near future[123]. - Grant funding recognized for the nine months ended September 30, 2025, was $4.0 million, compared to $7.6 million for the same period in 2024[123]. - Grant revenue decreased to $0.3 million for the three months ended September 30, 2025, down from $1.9 million in 2024, representing an 83% decline due to the completion of the Initial Phase of the RewinD-LB Trial[132]. - For the nine months ended September 30, 2025, grant revenue was $4.0 million, down 47% from $7.6 million in 2024, attributed to the transition phases of the RewinD-LB Trial[141]. Operating Expenses - Total operating expenses for the three months ended September 30, 2025, increased to $8.4 million, a 14% rise from $7.3 million in 2024, driven by higher research and development costs[131]. - Research and development expenses rose to $6.0 million for the three months ended September 30, 2025, an 18% increase from $5.1 million in 2024, primarily due to a $1.1 million increase in personnel costs[135]. - Total research and development expenses for the nine months ended September 30, 2025, were $16.0 million, a 37% increase from $11.7 million in 2024, mainly due to increased personnel and CMC-related costs[145]. - General and administrative expenses for the nine months ended September 30, 2025, totaled $8.0 million, a 16% increase from $6.9 million in 2024, driven by higher personnel costs and insurance expenses[146]. - The company expects to continue incurring losses and increasing research and development expenses, general and administrative expenses, and capital expenditures in the foreseeable future[153]. Clinical Trials and Research - The RewinD-LB Trial demonstrated a 54% risk reduction in clinically significant worsening compared to control at Week 32 of Batch B neflamapimod treatment (p=0.0037)[116]. - The planned Phase 3 clinical trial will evaluate neflamapimod in approximately 300 patients with DLB, expected to start in the second half of 2026[117]. - The company has received Orphan Drug Designation for neflamapimod for certain forms of frontotemporal dementia (FTD) in November 2024[118]. - The RewinD-LB Trial included 159 participants, funded primarily by a $21.3 million grant from the NIA[115]. - The company plans to implement manufacturing improvements to ensure the stability of neflamapimod's active ingredient in future trials[119]. Losses and Cash Flow - Net loss for the three months ended September 30, 2025, was $7.7 million, a 63% increase compared to a net loss of $4.8 million in 2024[131]. - For the nine months ended September 30, 2025, net cash used in operating activities was $16.9 million, compared to $8.5 million for the same period in 2024, representing a 99% increase in cash outflow[157][158]. - The net loss for the nine months ended September 30, 2025, was $18.9 million, up from a net loss of $9.6 million in the same period of 2024, indicating a 97% increase in losses[158][159]. - The company incurred a non-cash expense of $1.1 million for stock-based compensation during the nine months ended September 30, 2025[158]. Financing and Future Outlook - The company plans to finance its cash needs through equity offerings, debt financings, or other capital sources, which may dilute existing stockholders' ownership[154]. - The company is actively seeking additional financing to advance its product candidates and fund operations, but may face challenges in raising funds on favorable terms[154]. - The company has no off-balance sheet arrangements that could materially affect its financial condition[164].

Clinical Trials and Research - The company has received FDA clearance for the Type I Diabetes (CELZ-201 CREATE-1) IND application, allowing the initiation of a Phase I/II clinical trial [80]. - In April 2023, the company reported a 93% overall efficacy in a study of 30 patients treated with CELZ-001 for Type 2 Diabetes, demonstrating at least a 50% reduction in insulin requirement [84]. - The ImmCelz™ (CELZ-100) platform requires 75% fewer donor patient cells compared to industry standards, with a final product purity greater than 95% [86]. - The company has successfully generated human induced pluripotent stem cells (iPSCs)-derived islet cells that produce human insulin, indicating potential for clinical translation [88]. - The company initiated a program combining AI with its proprietary iPSC to diagnose and treat patients exposed to biological and chemical weapons, enhancing research efficiency and innovation [89]. - The company completed dosing the second cohort of 10 patients in the CELZ-201 ADAPT clinical trial, with no dose-limiting toxicities reported [91]. - The company has filed for Orphan Drug Designation for the treatment of Brittle Type 1 Diabetes using its ImmCelz™ platform, receiving the designation in March 2024 [83]. - The AlloStemSpine® Chronic Lower Back Pain trial will enroll 30 individuals, evaluating safety, efficacy, and tolerability of the treatment [85]. - The company has expanded its development and acquisition of intellectual property beyond urology to include treatments for neurologic disorders and other diseases [76]. Financial Performance - There was no revenue generated for the three-month periods ended September 30, 2025, and 2024 [96]. - No gross profits were reported for the three-month periods ended September 30, 2025, and 2024 [100]. - General and administrative expenses for the three-months ended September 30, 2025, totaled $776,821, an increase of $278,214 or 56% compared to the same period last year [101]. - Research and development expenses for the three-months ended September 30, 2025, totaled $465,154, a decrease of $116,642 or 20% from the previous year [103]. - The operating loss for the three-months ended September 30, 2025, was $1,273,034, compared to $1,109,674 for the same period last year [104]. - The net loss for the three-months ended September 30, 2025, was $1,235,934, compared to a net loss of $1,040,135 for the same period last year [105]. - Gross revenue for the nine-months ended September 30, 2025, was $3,000, down from $8,000 for the comparable period last year [107]. - General and administrative expenses for the nine-months ended September 30, 2025, totaled $2,396,735, an increase of $550,558 or 30% compared to the previous year [109]. - Research and development expenses for the nine-months ended September 30, 2025, totaled $1,709,719, a decrease of $219,218 or 11% from the previous year [111]. - The operating loss for the nine-months ended September 30, 2025, was $4,197,032, compared to $3,858,127 for the same period last year [112]. - The net cash used in operating activities for the nine-months ended September 30, 2025, was $3,918,891, an increase of $567,135 or 17% from the previous year [115].

Financial Performance - Total revenues for Q3 2025 reached $5,525,975, an increase from $4,791,696 in Q3 2024, representing a growth of 15.3%[36] - Net income attributable to KKR & Co. Inc. for Q3 2025 was $859,927, compared to $600,550 in Q3 2024, reflecting a year-over-year increase of 43%[38] - Total investment income for Q3 2025 was $1,697,857, up from $1,598,873 in Q3 2024, marking a growth of 6.2%[37] - KKR reported a net income of $3,878,784 for the nine months ended September 30, 2025, compared to $3,521,754 for the same period in 2024, reflecting an increase of approximately 10.2%[46] - The company reported a total capital allocation-based income of $2,708,601 for the nine months ended September 30, 2025, down from $3,164,491 in 2024, a decrease of 14.4%[78] - The company reported a total asset loss of $489.77 million for the nine months ended September 30, 2025, compared to a loss of $104.72 million for the same period in 2024, indicating a significant decline in asset performance[195] Assets and Liabilities - Total assets increased to $398,480,928 as of September 30, 2025, up from $360,099,411 on December 31, 2024, representing a growth of approximately 10.5%[27] - Total liabilities grew to $323,078,973, compared to $298,114,719 at the end of 2024, marking an increase of about 8.4%[28] - Stockholders' equity increased to $73,041,559 as of September 30, 2025, up from $60,399,515, indicating a growth of approximately 21%[28] - Total assets for Asset Management and Strategic Holdings increased to $64,358,457, up from $62,997,409, reflecting a growth of approximately 2.16%[170] - Total assets across all segments reached $100,835,381, reflecting a significant increase from $94,734,983[170] - Total liabilities for Asset Management and Strategic Holdings increased from $98,327 million to $103,926 million, reflecting a change of $5,599 million[179] Investments - Investments rose to $118,617,813, an increase of 11.5% from $106,453,051 as of December 31, 2024[27] - The total investments in insurance increased to $186,499,370, up from $170,144,744, representing a growth of approximately 9.6%[27] - Total investments increased to $305.12 billion as of September 30, 2025, up from $276.60 billion on December 31, 2024, representing a growth of 10.3%[90] - KKR's investments purchased in insurance totaled $69,675,125 for the nine months ended September 30, 2025, compared to $60,261,313 in 2024, reflecting an increase of about 15.5%[49] Cash and Cash Equivalents - Cash and cash equivalents in asset management and strategic holdings increased to $13,561,041, up from $8,535,048, reflecting a growth of 58.5%[27] - Cash, cash equivalents, and restricted cash increased to $22,886,489 at the end of the period, up from $14,962,439 in the prior year, representing a growth of approximately 52.9%[47] Earnings Per Share - Basic earnings per share for Q3 2025 were $0.97, up from $0.68 in Q3 2024, representing a growth of 42.6%[38] Expenses - Total expenses for Q3 2025 were $5,024,271, compared to $4,746,005 in Q3 2024, which is an increase of 5.9%[36] - The company reported net investment-related gains of $351,800 in Q3 2025, a recovery from a loss of $(235,971) in Q3 2024[36] Insurance Segment - Net premiums in the insurance segment for Q3 2025 were $1,059,610, significantly higher than $621,218 in Q3 2024, indicating a growth of 70.6%[36] - The company reported net policy benefits and claims amounted to $7.58 billion, a decrease from $11.88 billion in the same period of 2024[209] Goodwill and Intangible Assets - The carrying value of Goodwill increased to $544,871 million as of September 30, 2025, from $509,561 million as of December 31, 2024, reflecting a growth of approximately 6.9%[218] - The company reported a total insurance intangible asset balance of $5.59 billion as of September 30, 2025, compared to $5.20 billion at the end of 2024, indicating an increase in intangible assets[196] Reinsurance and Collateral - As of September 30, 2025, Global Atlantic held $47.4 billion in collateral for its reinsurers, compared to $46.6 billion as of December 31, 2024[209] - The total credit exposure associated with reinsurance recoverable and funds withheld as of September 30, 2025, was $4.26 billion, slightly down from $4.35 billion as of December 31, 2024[205] Accounting Standards and Compliance - The adoption of ASU 2024–01 regarding stock compensation did not have a material impact on KKR's consolidated financial statements[72] - KKR is evaluating the impact of ASU 2023–09 on its consolidated financial statements, which aims to enhance income tax disclosures[73] Market Conditions and Valuation - The average price per barrel of oil equivalent (BOE) in the Energy sector is $42.40, with a range of $41.05 to $45.25, suggesting an increase in valuation[183] - The corporate fixed securities have a fair value of $14,838,670, with a discount spread of 2.3%, suggesting a decrease in valuation[184]

Acquisitions and Divestitures - The company completed the divestiture of its Residential Mortgage Banking segment effective June 30, 2025, classifying it as a discontinued operation [398]. - The company acquired United Development Funding IV on March 13, 2025, with each outstanding common share converting into 0.416 shares of company common stock and contingent value rights [400]. - The company acquired Funding Circle for approximately $41.2 million in cash on July 1, 2024, integrating its loan origination servicing platform with the company's offerings [401]. - The company acquired Madison One for an initial purchase price of approximately $32.9 million on June 5, 2024, with additional payments based on performance metrics [402]. Financial Performance - Net income from continuing operations for the three months ended September 30, 2025, was $(16,947) thousand, compared to $(7,473) thousand for the same period in 2024 [410]. - Distributable earnings for the nine months ended September 30, 2025, were $(180,768) thousand, a significant decline from $28,093 thousand in 2024 [410]. - Total loan investment activity for the three months ended September 30, 2025, was $421,807 thousand, down from $685,879 thousand in 2024 [414]. - Consolidated net loss for Q3 2025 was $16.7 million, an increase of $9.5 million from Q3 2024, driven by net realized losses on financial instruments and real estate [443]. - Consolidated net income for the nine months ended September 30, 2025, was $11.6 million, an increase of $127.2 million from the same period in 2024, primarily due to a gain on bargain purchase from the UDF IV Merger and a decrease in valuation allowance [444]. Liquidity and Capital Resources - The company emphasizes the importance of liquidity and capital resources to fund ongoing obligations and address upcoming debt maturities [389]. - As of September 30, 2025, the company had approximately $150.0 million in unrestricted cash and $830.0 million in unencumbered assets [451]. - The company expects approximately $425.0 million in net liquidity from portfolio maturities and pending asset resolutions over the next 12 months [451]. - The company anticipates utilizing resources and access to capital markets to meet liquidity needs, including potential adjustments to the dividend rate [452]. Interest Income and Expense - Total interest income decreased by $89,046 thousand to $137,491 thousand in Q3 2025 compared to Q3 2024, primarily due to lower loan balances and interest rates [423]. - Interest expense decreased by $48,601 thousand to $126,971 thousand in Q3 2025 compared to Q3 2024, driven by decreased loan balances and interest rates [423]. - Year-to-date interest income for 2025 was $353,097 thousand, down $243,000 thousand from 2024, mainly due to increased non-accrual loans and decreased loan balances [430]. - Year-to-date interest expense for 2025 was $342,998 thousand, a decrease of $124,720 thousand from 2024, driven by lower loan balances and interest rates [430]. Loan Portfolio and Credit Quality - As of September 30, 2025, approximately 81% of the loans in the portfolio were floating rate loans, while 19% were fixed rate loans [406]. - The allowance for credit losses is reviewed quarterly, considering credit quality indicators such as LTV ratio and economic conditions [502]. - The company utilizes loan loss forecasting models to estimate expected lifetime credit losses at the individual loan level [503]. - Provision for loan losses was $31,000 thousand in Q3 2025, a decrease of $18,260 thousand from Q3 2024, primarily due to loan sales [427]. Debt and Financing - The total carrying amount of debt is $1,387,775,000, with senior secured notes totaling $721,151,000 and corporate debt totaling $666,624,000 [480]. - The Company issued $350 million of 4.50% Senior Secured Notes due 2026, with interest payable semiannually [480]. - The Company completed the sale of $220 million of 9.375% Senior Secured Notes due 2028, with net proceeds of $216.7 million before expenses [484]. - The total leverage ratio as of September 30, 2025, was 3.1x, with a recourse leverage ratio of 1.4x [458]. - The company maintains a diversified debt structure with varying maturity dates and interest rates, enhancing financial flexibility [476]. Dividends and Stockholder Equity - The company declared dividends of $0.125 per common share for the three months ended September 30, 2025, down from $0.25 in 2024 [410]. - Total stockholders' equity was $1.9 billion, a decrease of $60.5 million from December 31, 2024, mainly due to dividends paid and common stock repurchased [419]. - The company must distribute at least 90% of its REIT taxable income to qualify as a REIT, which may differ from distributable earnings due to certain non-cash items [440]. Market and Economic Conditions - The company reported that the U.S. Federal Reserve delivered its first interest rate cut since November 2024, impacting the economic outlook [407]. - The company is monitoring the impact of shifts in interest rates, credit spreads, and inflation on its operations and liquidity [453].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________________ to ____________________ Commission File Number: 001-38093 Veritone, Inc. (Exact name of registrant as specified in its charter) (888) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-32410 CELANESE CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 98- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________ FORM 10-Q ________________________________________________________________________________________________________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . 001-35542 (Commission File number) (Exact name of registrant as specified in its charter) Customers Bancorp, Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Pennsylvania 27-2290659 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38462 ___ ...